AlloVir Q2 EPS $(0.48) Misses $(0.44) Estimate; Cash, Cash Equivalents, And Short-Term Investments Of $246.5M Providing Cash Runway Into 2025
Portfolio Pulse from Benzinga Newsdesk
AlloVir reported Q2 losses of $(0.48) per share, missing the analyst consensus estimate of $(0.44) by 9.09%. However, this is a 30.43% increase over losses of $(0.69) per share from the same period last year. The company's cash, cash equivalents, and short-term investments total $246.5M, providing a cash runway into 2025.
August 04, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AlloVir's Q2 earnings missed estimates, but losses have improved compared to last year. The company's cash position is strong, providing a runway into 2025.
AlloVir's missed earnings could negatively impact the stock price in the short term. However, the year-over-year improvement in losses and strong cash position could provide some stability.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100